Interview: David Main – CEO and President, Aquinox Pharmaceuticals, Canada

David Main, CEO and president of Aquinox Pharmaceuticals Inc., introduces the company he founded in 2006, which now is in the late stages of development of a drug targeting the SHIP1 enzyme, with a focus on treating interstitial cystitis/bladder pain syndrome. Other applications may include blood cancers and chronic prostatitis/chronic pelvic pain syndrome. Aquinox Pharmaceuticals has the ambition to become a global biotechnology player. How was Aquinox Pharmaceuticals founded and what have been the beginnings of the company?
"Health Canada has done a good job of harmonizing the approval process based upon safety and efficacy, but there are numerous agencies, both federal and provincial, involved in pricing and reimbursement."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Register
Already a member? Sign In

Related Interviews

Latest Report